{"prompt": "['Protocol RS-001', 'Confidential', 'PROTOCOL SYNOPSIS', 'TITLE', 'Phase 1 study of ABI-009 (nab-rapamycin) for Surgically-Refractory', 'Epilepsy (RaSuRE)', 'SPONSOR-', 'Jason S. Hauptman, MD, PhD', 'INVESTIGATOR', \"Seattle Children's Hospital\", '4800 Sand Point Way NE', 'Seattle, WA 98105', 'FUNDING', 'AADi Bioscience, Inc.', 'ORGANIZATION', \"Seattle Children's Hospital\", 'NUMBER OF', '1', 'SITES', 'RATIONALE', 'Seizures that are refractory to both medical and surgical therapy', 'increase the risk of morbidity and mortality in children with epilepsy.', 'At this point in time, options for these children are sparse and', 'suboptimal. This hypothesis-driven phase 1 study aims to evaluate the', 'use of a mammalian target of rapamycin mTOR] inhibitor, ABI-009,', 'in', 'this subset of challenging participants. The underlying hypotheses being', 'tested in trial are: (1) ABI-009 is a safe and well-tolerated medication in', 'children who have medically-refractory epilepsy and have failed', 'epilepsy surgery, and (2) The addition of ABI-009 therapy to the', 'current clinical standard of continued antiepileptic medications results', 'in improved epilepsy control. This is unique among trials of anti-', 'epileptic medications in that it also studies mTOR inhibition in a non-', 'Tuberous Sclerosis Complex (TSC) specific population for whom few', 'additional effective therapies exist.', 'STUDY DESIGN', 'This is a prospective, single-center, phase 1 safety study to investigate', 'the safety, tolerability, seizure control, and quality of life in participants', 'with medically-refractory epilepsy who failed epilepsy surgery. These', 'participants will have continued seizures despite being at least 3 months', 'post-epilepsy surgery (resective surgery with an intent to cure). Upon', 'enrollment, participants will be continued and observed on their pre-', 'existing, clinically prescribed antiepileptic drug (AED) regimen for 1', 'month. At the 1-month mark, participants will receive weekly ABI-009', 'intravenously at different dose levels in cohorts of 3 participants each', 'using the standard 3+3 dose-finding design. ABI-009 will be continued', 'for a total of 3 weeks. ABI-009 will then be discontinued and the', 'participants will be observed for an additional 3 months. We intend an', 'expansion of the maximum tolerated dose (MTD) cohort to an', 'estimated additional 6 participants for a maximum possible enrollment', 'of 18 participants.', 'DURATION OF', 'Participants will be on study for about five months.', 'SUBJECT', 'Initial control period: 1 month', 'PARTICIPATION', 'Dosing period: 3 weeks', 'Version 2', 'Version Date: October 31, 2018', 'Page 9 of 72']['Protocol RS-001', 'Confidential', 'AND DURATION', 'Follow-up: 3 months', 'OF STUDY', 'PRIMARY', 'Safety and Tolerability:', 'OBJECTIVE', 'Determine dose-limiting toxicities (DLTs) and MTD of ABI-', '009 in participants with surgically-refractory epilepsy', 'Record the adverse events (AEs) and document their severity', 'with ABI-009 dosing for medically intractable epilepsy that has', 'failed surgical resection, administered in conjunction with their', 'pre-existing AED regimen. Record the compliance of families', 'with medication and record the number of participants that', 'withdraw from study either voluntarily or by necessity', 'secondary to AEs.', 'Columbia-Suicide Severity Rating Scale (C-SSRS) serious', 'suicidal ideation score stays below a 4 rating.', 'SECONDARY', 'Efficacy and Quality of Life:', 'OBJECTIVES', 'Efficacy is defined as the change from in seizure frequency between', 'baseline and follow-up, expressed as percentage reduction in seizure', 'rate (reduction in seizure frequency from baseline, calculated as', '(Baseline frequency [seizures/week] - frequency at follow-up', '[seizures/week])/Baseline frequency [seizures/week]) and median', 'percentage reduction in seizure frequency. Treatment response rate', 'will be defined as the proportion of participants achieving at least a', '25% reduction in seizure frequency from baseline. Seizure frequency', 'will be defined as the ratio between the number of seizures and the', 'number of days on which seizure information was known within the', 'same period of time (for either baseline or maintenance phase).', 'Additional secondary endpoints will include frequency of seizure-free', 'days during the maintenance period, seizure-free rate (participants', 'remaining seizure free during the entire maintenance period), and', 'rapamycin blood level-response relationship analysis.', 'Evaluate quality of life indices for participants before, during, and after', 'dosing with ABI-009 in conjunction with pre-existing AED regimens.', 'NUMBER OF', 'Up to 18', 'PARTICIPANTS', 'PARTICIPANT', 'Inclusion Criteria:', 'SELECTION', '1. Written informed consent (and assent when applicable) obtained', 'CRITERIA:', \"from participant or participant's legal representative\", 'Inclusion Criteria', '2. Willingness and able to adhere to the study visit schedule and other', 'protocol requirements', '3. Male or female >3 and 26 years of age at Visit 1', 'a.', 'Because no dosing or adverse event data are currently', 'available on the use of ABI-009 in participants years of', 'Version 2', 'Version Date: October 31, 2018', 'Page 10 of 72']\n\n###\n\n", "completion": "END"}